<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Poverty-related and neglected diseases Á an economic and epidemiological analysis of poverty relatedness and neglect in research and development</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Peter</forename><surname>Von Philipsborn</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Faculty of Medicine</orgName>
								<orgName type="institution">Technische Universita ¨t Mu ¨nchen</orgName>
								<address>
									<settlement>Munich</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="laboratory">Universities Allied for Essential Medicines Europe e.V. (UAEM)</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Fridolin</forename><surname>Steinbeis</surname></persName>
							<affiliation key="aff1">
								<orgName type="laboratory">Universities Allied for Essential Medicines Europe e.V. (UAEM)</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="institution">Charite ´Universita ¨tsmedizin Berlin</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Max</forename><forename type="middle">E</forename><surname>Bender</surname></persName>
							<affiliation key="aff1">
								<orgName type="laboratory">Universities Allied for Essential Medicines Europe e.V. (UAEM)</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="department">Institute for Social Medicine, Epidemiology and Health Economics</orgName>
								<orgName type="institution">Charite ´Universita ¨tsmedizin Berlin</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Sadie</forename><surname>Regmi</surname></persName>
							<affiliation key="aff1">
								<orgName type="laboratory">Universities Allied for Essential Medicines Europe e.V. (UAEM)</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff4">
								<orgName type="department">Institute for Science, Ethics and Innovation</orgName>
								<orgName type="institution">University of Manchester</orgName>
								<address>
									<settlement>Manchester</settlement>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Peter</forename><surname>Tinnemann</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">Institute for Social Medicine, Epidemiology and Health Economics</orgName>
								<orgName type="institution">Charite ´Universita ¨tsmedizin Berlin</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Poverty-related and neglected diseases Á an economic and epidemiological analysis of poverty relatedness and neglect in research and development</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">66FF6CD02A2656012DAA6985739CBD57</idno>
					<idno type="DOI">10.3402/gha.v8.25818</idno>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:31+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Background: Economic growth in low-and middle-income countries (LMIC) has raised interest in how disease burden patterns are related to economic development.</s><s>Meanwhile, poverty-related diseases are considered to be neglected in terms of research and development (R&amp;D).</s><s>Objectives: Developing intuitive and meaningful metrics to measure how different diseases are related to poverty and neglected in the current R&amp;D system.</s><s>Design: We measured how diseases are related to economic development with the income relation factor (IRF), defined by the ratio of disability-adjusted life-years (DALYs) per 100,000 inhabitants in LMIC versus that in high-income countries.</s><s>We calculated the IRF for 291 diseases and injuries and 67 risk factors included in the Global Burden of Disease Study 2010.</s><s>We measured neglect in R&amp;D with the neglect factor (NF), defined by the ratio of disease burden in DALYs (as percentage of the total global disease burden) and R&amp;D expenditure (as percentage of total global health-related R&amp;D expenditure) for 26 diseases.</s><s>Results: The disease burden varies considerably with the level of economic development, shown by the IRF (median: 1.38; interquartile range (IQR): 0.79Á6.3).</s><s>Comparison of IRFs from 1990 to 2010 highlights general patterns of the global epidemiological transition.</s><s>The 26 poverty-related diseases included in our analysis of neglect in R&amp;D are responsible for 13.8% of the global disease burden, but receive only 1.34% of global healthrelated R&amp;D expenditure.</s><s>Within this group, the NF varies considerably (median: 19; IQR: 6Á52).</s><s>Conclusions: The IRF is an intuitive and meaningful metric to highlight shifts in global disease burden patterns.</s><s>A large shortfall exists in global R&amp;D spending for poverty-related and neglected diseases, with strong variations between diseases.</s></p><p><s>Keywords: poverty-related and neglected diseases; neglected tropical diseases; research and development; disease burden; double burden; global burden of disease; research and development expenditure</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>O ver the past 20 years, rapid economic change in low and middle income countries has raised interest in how disease burden patterns are related to economic development.</s><s>It is commonly held that in the course of the global epidemiological transition, a growing number LMIC face a double burden of both povertyrelated, communicable diseases and affluence-related, noncommunicable diseases at the same time <ref type="bibr" target="#b0">(1,</ref><ref type="bibr" target="#b1">2)</ref>.</s><s>Meanwhile, poverty-related diseases are still considered to be neglected in research and development (R&amp;D).</s><s>While affluence-related diseases may attract considerable commercial R&amp;D funding, many poverty-related diseases are considered neglected in the current R&amp;D system (3Á10).</s><s>Differing assessments of the extent and relevance of this so-called R&amp;D gap influence the broader debate on global health R&amp;D policy <ref type="bibr" target="#b4">(5,</ref><ref type="bibr" target="#b10">11,</ref><ref type="bibr" target="#b11">12)</ref>.</s><s>Concerns about these issues have led to negotiations on a possible Global Health R&amp;D Convention, as proposed by the Consultative Expert Working Group on Research and Development (CEWG) commissioned by the World Health Organization (WHO), subsequent debates on a Global Health R&amp;D Observatory, and ongoing WHO-sponsored R&amp;D demonstration projects <ref type="bibr">(5, 6, 13Á17)</ref>.</s></p><p><s>Based on a definition of Type I, II, and III diseases discussed in a background document prepared by the WHO Secretariat <ref type="bibr" target="#b17">(18)</ref> and by Røttingen et al. <ref type="bibr" target="#b12">(13)</ref>, we propose an income relation factor (IRF) as a quantitative, intuitive, and meaningful metric for the degree to which diseases, disease groups, and risk factors are related to the level of economic development.</s><s>Based on the IRF and work done by the WHO Secretariat <ref type="bibr" target="#b17">(18)</ref> and Røttingen et al. <ref type="bibr" target="#b12">(13)</ref>, who used disease burden data for 2004, we propose quantitative definitions for poverty-and affluence-related diseases based on data from the Global Burden of Disease Study 2010 (GBD 2010).</s><s>Moreover, we assess the size and the characteristics of the gap in R&amp;D for a subset of poverty-related diseases by comparing global R&amp;D expenditure and disease burden.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Methods</head><p><s>We conduct our analysis in two steps.</s><s>First, we analyze 291 diseases, injuries and cause groups, and 67 risk factors and risk factor clusters included in the GBD 2010 <ref type="bibr" target="#b18">(19,</ref><ref type="bibr" target="#b19">20)</ref> with regard to their relatedness to the level of economic development.</s><s>Second, we analyze the R&amp;D gap for 26 diseases and disease groups commonly defined as poverty related and neglected and for which sufficiently specific R&amp;D expenditure data were available, by comparing disease burden and R&amp;D expenditure.</s><s>An overview of our methodology is given in Fig. <ref type="figure">1</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Total global disease burden and total global health-related research and development (R&amp;D) expenditure</head><p><s>Global Burden of Disease Study 2010(GBD 2010): 241 diseases, 51 cause groups and 67 risk factors of death and disability causing 2.490 billion disability-adjusted life years (DALYs) in 2010 <ref type="bibr" target="#b18">(Murray et al. 2012 and</ref><ref type="bibr" target="#b19">Lim et al. 2012)</ref>.</s></p><p><s>Total world-wide health related R&amp;D expenditure: 265.9 billion US$(2008-2012 annual average) <ref type="bibr" target="#b24">(Chakma et al. 2014)</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Relatedness of diseases to the level of economic development</head><p><s>Measured with the income relation factor (IRF):</s></p><p><s>(DALYs = disability-adjusted life years, LMIC = low and middle income countries, HIC = high income countries)</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>R&amp;D expenditure and neglect in R&amp;D</head><p><s>Measured with the neglect factor (NF):</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Relatedness of diseases to the level of economic development</head><p><s>In 2001, the WHO Commission on Macroeconomics and Health proposed a scheme for classifying diseases according to their relatedness to the level of economic development which distinguishes three disease types (disease Types I, II, and III, see Table <ref type="table" target="#tab_4">1</ref>) <ref type="bibr" target="#b17">(18,</ref><ref type="bibr" target="#b20">21)</ref>.</s><s>The WHO Secretariat <ref type="bibr" target="#b17">(18)</ref>, as well as Røttingen et al. <ref type="bibr" target="#b12">(13)</ref>, propose the following ratio to operationalize this classification scheme, based on DALY figures (disability-adjusted life years, a composite figure that captures both premature mortality and the prevalence and severity of ill-health) for different world regions:</s></p><p><s>DALYs per 100; 000 inhabitants in low-and middle-income countries DALYs per 100; 000 inhabitants in high-income countries</s></p><p><s>We use the term income relation factor (IRF) for this ratio.</s><s>We define Type III diseases (IRF ]35) as strongly poverty related, and Type II diseases (3 ]IRF B35) as moderately poverty related.</s><s>To accommodate all conditions, and not just those related to poverty, we expand the existing classification by subdividing the group of Type I diseases (0]IRF B3) into three groups: conditions unrelated to economic development (Type Ic, 0.66]IRFB3), moderately affluence-related conditions (Type Ib, 0.33] IRF B0.66), and strongly affluence-related conditions (Type Ia, IRF B0.33).</s><s>We then calculate the IRF for all diseases, injuries and cause groups included in the GBD 2010 and categorize them according to the above definitions.</s><s>An overview of the different disease categories and their definitions is given in Table <ref type="table" target="#tab_4">1</ref>.</s><s>Based on DALYs attributable to the independent effects of risk factors and risk factor clusters as estimated by the GBD 2010, we calculate the IRF for the 67 risk factors and risk factor clusters included in the GBD 2010 <ref type="bibr" target="#b19">(20)</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>R&amp;D expenditure and neglect in R&amp;D</head><p><s>In the term neglected diseases, the word neglect refers to the notion that for the diseases in question, the proportion of current R&amp;D efforts is considered to fall short of the proportion which would be equitable and efficient under the given conditions.</s><s>In our operationalization of neglect, we use R&amp;D expenditure as a yardstick for current R&amp;D efforts, as it reflects both the commercial interest of industry and the political commitment of governments and philanthropy.</s><s>We use the contribution of diseases to the global disease burden measured in DALYs as an incomplete and controversial proxy for the proportion of R&amp;D efforts which should ideally be directed toward specific diseases.</s><s>To quantify the magnitude of the imbalance between R&amp;D efforts and assumed R&amp;D needs for specific diseases Á that is, the size of the R&amp;D Gap Á we calculate the R&amp;D expenditure in US$ per DALY for individual diseases and disease groups.</s><s>This metric has been used in previous studies on neglect in R&amp;D <ref type="bibr" target="#b5">(6,</ref><ref type="bibr" target="#b12">13,</ref><ref type="bibr" target="#b21">22,</ref><ref type="bibr" target="#b22">23)</ref>.</s><s>In addition, we propose the neglect factor (NF) as a new summary measure, with the following definition:   <ref type="bibr" target="#b20">(21)</ref>.</s></p><p><s>Diseases for which the disease burden in LMIC is at least three but not more than 35 times higher than in HIC <ref type="bibr" target="#b12">(13,</ref><ref type="bibr" target="#b17">18)</ref>.</s></p><p><s>Type II diseases, or moderately poverty-related diseases, with 3 ]IRF B35 <ref type="bibr" target="#b12">(13,</ref><ref type="bibr" target="#b17">18)</ref>.</s></p><p><s>Disease type III Type III diseases are diseases 'that are overwhelmingly or exclusively incident in developing countries' <ref type="bibr" target="#b20">(21)</ref>.</s></p><p><s>Diseases for which the disease burden in LMIC is more than 35 times higher than in HIC <ref type="bibr" target="#b12">(13,</ref><ref type="bibr" target="#b17">18)</ref>.</s></p><p><s>Type II diseases, or strongly poverty-related diseases, with IRF ]35 <ref type="bibr" target="#b12">(13,</ref><ref type="bibr" target="#b17">18)</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Poverty-related and neglected diseases</head><p><s>Citation: Glob Health Action 2015, 8: 25818http://dx.doi.org/10.3402/gha.v8.25818</s></p><p><s>For R&amp;D expenditure, we used data provided by G-FINDER (Global Funding of Innovation for Neglected Diseases) <ref type="bibr" target="#b22">(23,</ref><ref type="bibr" target="#b23">24)</ref> and Chakma et al. <ref type="bibr" target="#b24">(25)</ref>.</s><s>G-FINDER includes comprehensive R&amp;D expenditure data on 30 diseases fulfilling three criteria: 1) the disease disproportionately affects people in developing countries; 2) there is a need for new pharmaceutical products; and 3) there is a market failure, that is, a commercial market insufficient to attract industry R&amp;D <ref type="bibr" target="#b22">(23)</ref>.</s><s>Of these 30 diseases, we exclude four diseases which are not included in GBD 2010, and for which we therefore lack comparable disease burden data (see methodological appendix, Supplementary file 1, for details).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Development and regional distribution of the burden of poverty-related and neglected diseases</head><p><s>To track the public health relevance of poverty-related and neglected diseases (PRND) over time, and to understand possible reasons for their neglect, we analyze the development of the disease burden caused by PRND over the past 20 years, and the geographical distribution of the disease burden over the 21 regions covered in GBD 2010.</s><s>For all figures based on GBD 2010 data, we calculate 95% uncertainty intervals based on the 95% uncertainty intervals as reported in GBD 2010 (please refer to the methodological appendix, Supplementary file 1, for details).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Relatedness of diseases, injuries, and risk factors to the level of economic development</head><p><s>In 2010, the overall IRF for all causes was 1.4, indicating an approximately 1.4 times higher total disease burden per capita in LMIC compared to high-income countries (HIC).</s><s>This is a decrease from 1990, when the overall IRF was 1.8.</s><s>The relatedness of major disease groups to the level of economic development is presented in Table <ref type="table" target="#tab_0">2</ref>. Data for all 291 diseases, injuries, and cause groups included in the GBD 2010 are presented in Supplementary file 2. Table <ref type="table" target="#tab_1">3</ref> presents the IRF for the main risk factor clusters analyzed in GBD 2010 (data on all 67 risk factors are provided in Supplementary file 3).</s><s>In 2010, the disease burden attributable to risk factors associated with unimproved water and sanitation, as well as child and maternal undernutrition, was much higher in LMIC than in HIC (IRF 107 and 34, respectively).</s><s>By contrast, the disease burden attributable to dietary risk factors, physical inactivity, physiological risk factors, alcohol and drug use, and tobacco smoking was 10Á20% higher in HIC than in LMIC, resulting in an IRF between 0.9 and 0.8 (up from 0.7 to 0.6 in 1990).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>R&amp;D expenditure and neglect in R&amp;D</head><p><s>Between 2008 and 2012, for the 26 PRND included in our analysis of neglect, on average a total of US$3,556 million (in nominal 2012 US$) was spent on R&amp;D annually, based on G-FINDER data <ref type="bibr" target="#b22">(23,</ref><ref type="bibr" target="#b23">24)</ref>.</s><s>In the same time period, US$265,920 million (in nominal 2012 US$) was spent in average annually on total healthrelated R&amp;D worldwide, based on figures published by Chakma et al. <ref type="bibr" target="#b24">(25)</ref>.</s><s>Thus, between 2008 and 2012, 1.34% of total global health-related R&amp;D expenditure was spent on the 26 PRND included in our analysis.</s></p><p><s>Of 2,490 million DALYs lost in 2010 to all causes of death and disability, 13.8% were caused by the 26 PRND included in our analysis (for details on each of these, see Fig. <ref type="figure">2</ref> and Table <ref type="table" target="#tab_2">4</ref>).</s><s>From 2008 to 2012, on average 107 US$ per DALY was spent on health-related R&amp;D annually.</s><s>For the 26 PRND in our analysis, only 10.3 US$ per DALY was spent Á 10 times less than the global average for all diseases.</s><s>This is summed up by the NF of 10.3 for these 26 diseases combined, showing that the proportion of the global disease burden caused by these diseases is roughly 10 times larger than the proportion of total global health-related R&amp;D expenditure spent on them.</s><s>Figures <ref type="figure" target="#fig_1">3 and 4</ref> show detailed results for the 26 diseases and diseases groups.</s><s>Figure <ref type="figure" target="#fig_2">5</ref> tracks the disease burden caused by these 26 diseases over the past 20 years, and Fig. <ref type="figure">6</ref> analyzes the geographical distribution of the disease burden caused by PRND.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p><s>Relatedness of diseases, injuries, and risk factors to the level of economic development Our analysis reveals that the number of poverty-related diseases is considerably larger than existing definitions of PRND suggest.</s><s>Of the 241 individual diseases and injuries analyzed in the GBD 2010, approximately one third (81) are either strongly or moderately poverty related, causing 38% of the global disease burden in 2010, down from 51% in 1990.</s></p><p><s>The existing Type I disease category (0 ]IRF B3), encompassing all diseases not related to poverty, contains 165 diseases and injuries, responsible for 61% of the global disease burden in 2010.</s><s>This disease group includes diseases such as Dengue (IRF 2.9), which causes three times more DALY per capita in LMIC compared to HIC, as well as diseases such as prostate cancer (IRF 0.16) causing approximately seven times more DALYs per capita in HIC than in LMIC.</s><s>The large range of this category, and the large number diseases included, warrant a substratification.</s></p><p><s>Based on our proposed substratification, 43 diseases and injuries are either strongly affluence related (Type Ia, IRF B0.33) or moderately affluence related (Type Ib, 0.33]IRF B0.66), causing 13.2% of the global disease burden, a figure which has remained comparatively stable since 1990.</s><s>In addition, approximately half of all diseases and injuries, responsible for half of the global disease  (19,917 Á 34,930) 1.4 (0.8 Á 2.6) Ic (Ic-Ic) 51,463 (36,115 Á 73,296) 28,629 (22,174 Á 36,789) 1.8 (1.0 Á 3.3) Ic (Ic-II)</s></p><p><s>Communicable, maternal, neonatal, and nutritional disorders 14,604 (10,322 Á 20,676) 1,416 (1,084 Á 1,869) 10.3 (5.5 Á 19.1) II (II-II) 26,602 (18,241 Á 39,060) 2,084 (1,628 Á 2,716) 12.8 (6.7 Á 24.0) II (II-II) Non-communicable diseases 19,079 (13,870 Á 25,683) 22,470 (16,895 Á 29,815) 0.8 (0.5 Á 1.5) Ic (Ib-Ic) 19,841 (14,360 Á 27,282) 23,442 (18,081 Á 30,168) 0.8 (0.5 Á 1.</s></p><formula xml:id="formula_0">HIV</formula><formula xml:id="formula_1">Á 3,246) 1.7 (1.0 Á 3.</formula><p><s>2) Ic (Ic-II) 5,020 (3,514 Á 6,954) 3,104 (2,466 Á 3,905) 1.6 (0.9 Á 2.8) Ic (Ic-Ic)  Tobacco smoking.</s><s>including secondhand smoke 2,208 (1,853 Á 2,540) 2,729 (2,376 Á 3,072) 0.8 (0.6 Á 1.1) Ic (Ib-Ic) 2,722 (2,306 Á 3,179) 3,696 (3,356 Á 4,070) 0.7 (0.6 Á 0.9) Ic (Ib-Ic) Alcohol and drug use 2,201 (1,901 Á 2,547) 2,718 (2,448 Á 2,997) 0.8 (0.6 Á 1.0) Ic (Ib-Ic) 2,039 (1,765 Á 2,371) 3,376 (3,090 Á 3,688) 0.6 (0.5 Á 0. Physiological risk factors 4,149 (3,766 Á 4,519) 4,764 (4,373 Á 5,215) 0.9 (0.7 Á 1.0) Ic (Ic-Ic) 3,608 (3,314 Á 3,937) 5,793 (5,426 Á 6,145) 0.6 (0.5 Á 0.  3,669 (3,347 Á 3,977) 3,924 (3,639 Á 4,248) 0.9 (0.8 Á 1.1) Ic (Ic-Ic) 3,132 (2,840 Á 3,435) 4,550 (4,194 Á 4,859) 0.7 (0.6 Á 0. Remarkably, this double burden has decreased since 1990, as the burden of non-communicable diseases has decreased simultaneously in LMIC and in HIC (IRF 0.8 constant since 1990), while the burden of communicable diseases has decreased more rapidly in LMIC than in HIC (IRF 10.3 in 2010, down from 12.8 in 1990).</s><s>The burden of injuries has decreased both in LMIC and in HIC, but slightly faster in HIC (IRF 1.7 in 2010, up from 1.6 in 1990).</s><s>Thus, while it is true that LMIC face actually a triple burden of communicable diseases, noncommunicable diseases, and injuries, this phenomenon has grown less acute since 1990.</s></p><p><s>Our analysis of the relatedness of risk factors to the level of economic development reveals similar patterns for the year 2010, showing a double burden of risk factors in LMIC: among the 10 major risk factor clusters analyzed in the GBD 2010, there are two which are strongly poverty related (unimproved water and sanitation, and child and maternal undernutrition), one which is moderately poverty related (air pollution) and seven which are unrelated to the level of economic development, causing a similar amount of DALYs in HIC and in LMIC.</s><s>Global disparities in risk factor exposure patterns were higher than those in disease burden patterns in 1990, and have converged more consistently since then.</s></p><p><s>Among the 81 strongly or moderately poverty-related conditions, a considerable number are infectious diseases which can be treated or prevented with existing pharmaceuticals.</s><s>For others, for example, accidents, intentional injuries, and certain maternal and neonatal conditions such as birth trauma and abortion, pharmaceuticals are of limited usefulness.</s><s>This shows that the lack of pharmaceutical R&amp;D on neglected diseases is only one among many health challenges specific to LMIC.</s><s>Moreover, this highlights that for a considerable number of povertyrelated causes of death and disability, policy action beyond the traditional field of health policy might be needed.</s><s>The relative contribution of these 26 PRND to the global disease burden has remained relatively stable over the past 20 years (13.8% in 2010 down from 14.4% in 1990), with shifting shares of individual PRND (see Fig. <ref type="figure" target="#fig_2">5</ref>).</s><s>By contrast, the role of the larger set of strongly and moderately poverty-related diseases identified in the first part of our analysis has decreased strongly from 51% of the global disease burden in 1990 to 38% in 2010.</s><s>This shows that the 26 PRND in our analysis are, unlike the larger set of poverty-related diseases, not only poverty related but also neglected.</s><s>While poverty-related diseases more generally are receding, the R&amp;D gap for PRND, and their contribution to the global disease burden, over the past 20 years, has not grown significantly smaller in the course of the global epidemiological transition.</s><s>It is therefore unlikely to disappear without increased action by public and private actors.</s><s>For this action to be effective, however, better data on PRND is needed, suggesting a rationale for a WHO Global Health R&amp;D Observatory <ref type="bibr" target="#b12">(13,</ref><ref type="bibr" target="#b16">17)</ref>.</s><s>Moreover, recent national and international policy initiatives such as the WHO R&amp;D Demonstration Projects should be considered in this context (27).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Limitations</head><p><s>In our categorization of diseases into diseases Types I, II, and III, we followed the approach used by the WHO Secreteriat and Røttingen et al., although noting limitations outlined by them <ref type="bibr" target="#b12">(13,</ref><ref type="bibr" target="#b17">18)</ref>.</s><s>The choice of the cut-off values between the different disease categories is arbitrary to a certain degree, which is aggravated by the fact that the relative size of the disease categories is highly sensitive to the cut-off value.</s><s>In addition, the DALY figures used are not age weighted.</s></p><p><s>Moreover, it should be noted that the IRF metric used in our analysis was originally developed for use with data from the GBD 2004 study, which uses a different methodology compared to the one used by GBD 2010.</s><s>Therefore, our results are not directly comparable to the results reported in the original WHO background document <ref type="bibr" target="#b16">(17)</ref> and Røttingen et al. <ref type="bibr" target="#b12">(13)</ref>.</s><s>(For details please refer to the methodological annex.)</s><s>It is also important to note that the IRF captures only health disparities across countries, and not those within countries.</s><s>Our analysis of neglect in R&amp;D based on R&amp;D expenditure and disease burden also has a number of limitations.</s><s>Even for diseases not related to poverty, additional R&amp;D needs specific to resource-poor settings may exist, which may not be addressed by commercially driven R&amp;D geared toward high-income settings.</s><s>This 'intradisease R&amp;D gap' is not captured by our analysis.</s><s>Moreover, the disease burden measured in DALYs is a very crude measure for R&amp;D needs.</s><s>The equitable and efficient level of R&amp;D on a specific disease might depend, among other things, on: 1) the relative epidemiological and public health relevance of the disease; 2) the suitability and viability of existing medical and non-medical prevention and treatment options, and thus the medical need for new or improved pharmaceuticals; 3) the scientific and technical prospects of successfully developing new or improved pharmaceuticals for the disease in question; 4) the potential contribution these new remedies could make in fighting the disease under the given political, economic, social, and socioeconomic conditions.</s><s>All four factors depend at least partly on facts which are unknown, uncertain, controversial, and/or difficult to assess in a systematic, comprehensive, and scientifically rigorous way, while only the first point is addressed by the DALY measure which we have used.</s><s>This is a considerable limitation.</s><s>Particularly important in light of the concentration of PRND in the poorest countries (see Fig. <ref type="figure">6</ref>) is that weak health systems limit access to existing drugs, and will severely limit the benefits of any new drugs for PRND.</s><s>This implies that measures to address the R&amp;D gap will only realize their full potential if complemented with a strengthening of national health systems.</s><s>Moreover, considerable uncertainties are attached to the data we have used in our analysis, namely the disease burden data and the R&amp;D expenditure data for total global biomedical R&amp;D and for specific neglected diseases, which we have taken from different sources <ref type="bibr" target="#b18">(19,</ref><ref type="bibr" target="#b19">20,</ref><ref type="bibr" target="#b22">23,</ref><ref type="bibr" target="#b23">24)</ref>.</s><s>For figures on specific neglected diseases, we used the G-FINDER, which uses very strict inclusion criteria and only considers funding data verified both by donors and receiving R&amp;D organizations <ref type="bibr" target="#b22">(23)</ref>.</s><s>This implies that G-FINDER data on R&amp;D funding are lower-bound estimates.</s><s>By contrast, for total world-wide biomedical R&amp;D expenditure, we used figures provided by Chakma et al., who use publicly reported as well as interpolated data <ref type="bibr" target="#b24">(25)</ref>.</s><s>Moreover, uncertainties are attached to the measures used by Chakma et al. for inflation and purchasing power adjustments, as pointed out by Young et al. <ref type="bibr" target="#b26">(28)</ref>.</s></p><p><s>For our own calculations, we used the National Institutes of Health Biomedical R&amp;D Price Index to adjust for inflation, which is an equally imperfect measure <ref type="bibr" target="#b26">(28)</ref>.</s><s>Uncertainties are also attached to the disease burden data we use <ref type="bibr" target="#b18">(19,</ref><ref type="bibr" target="#b19">20)</ref>.</s><s>These may be particularly large for the neglected tropical diseases we have analyzed <ref type="bibr" target="#b27">(29,</ref><ref type="bibr" target="#b28">30)</ref>.</s><s>Moreover, varying definitions of PRND exist <ref type="bibr">(3, 13, 23, 31Á33)</ref>, of which we have chosen only one.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results of similar studies</head><p><s>The results of our study are consistent with earlier studies on disparities in disease burden patterns and global health R&amp;D.</s><s><ref type="bibr">Røttingen</ref>   global DALYs for each condition had a small, significant negative relationship with the production of each type of MEDLINE articles for that condition (3).</s><s>Trouiller et al. had reported earlier that of 1,393 new chemical entities marketed between 1975 and 1999, only 16 or roughly 1% was for tropical diseases and tuberculosis, while these diseases were responsible for 11.4% of the global disease burden <ref type="bibr" target="#b10">(11)</ref>.</s><s>However, Cohen et al. found for the same time period and the same set of diseases a considerably higher number of new chemical entities (32 or roughly 2%) <ref type="bibr" target="#b32">(34)</ref>.</s><s>Viergever, Karam, and Terry find that for every million DALYs caused by communicable, maternal, perinatal, and nutritional conditions, by noncommunicable diseases, or by injuries, the WHO's International Clinical Trials Registry Platform (ICTRP) database contains an estimated 7.4, 52.4, and 6.0 trials, respectively <ref type="bibr" target="#b33">(35)</ref>.</s><s>Despite differences in methodology, scope, and time frame, these findings are consistent with the results of our analysis.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conclusions</head><p><s>The   Regional Distribution of the burden of poverty-related and neglected diseases (2010) Fig. <ref type="figure">6</ref>.</s><s>PRND are strongly concentrated in only three world regions: Western and Eastern sub-Saharan Africa, and South Asia together account for more than 60% of the global burden of PRND, illustrating the concentration of PRND in the poorest countries.</s><s>Source: Own calculations based on Global Burden of Disease Study 2010.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>*</head><label></label><figDesc><div><p><s>Correspondence to: Peter von Philipsborn, Faculty of Medicine, Technische Universita ¨t Mu ¨nchen, Stuntzstraße 12, DE-81667 Mu ¨nchen, Germany, Email: peter.philipsborn@alumni.lse.ac.uk</s><s>To access the supplementary material for this article, please see Supplementary files under 'Article Tools' Received: 25 August 2014; Revised: 3 November 2014; Accepted: 16 November 2014; Published: 22 January 2015</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Fig. 4 .</head><label>4</label><figDesc><div><p><s>Fig. 4. The neglect factor for 26 poverty-related diseases.</s><s>The neglect factor is the ratio of disease burden in DALYs (as a percentage of the total global disease burden, 2010) versus R&amp;D expenditure (as a percentage of total global health-related R&amp;D expenditure, 2008Á2012 average).</s><s>Source: Own calculations based on Global Burden of Disease Study 2010, G-FINDER data and data published by Chakma et al.</s><s>DALYs: disability adjusted life years; R&amp;D: research and development.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Fig. 5 .</head><label>5</label><figDesc><div><p><s>Fig. 5.</s><s>The overall contribution of PRND to the global burden of disease has remained comparatively stable over the past 20 years, with marked changes in the relative weight of individual disease.</s><s>Source: Own calculations based on Global Burden of Disease Study 2010.</s><s>Disease groups are defined as in G-FINGER, excluding four diseases for which no disease burden data were available.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 2</head><label>2</label><figDesc></figDesc><table><row><cell>241 causes of death and disability</cell></row><row><cell>16 strongly affluence related (Type Ia)</cell></row><row><cell>27 moderately affluence related (TypeIb)</cell></row><row><cell>117 unrelatedto the level of economic</cell></row><row><cell>development (Type Ic)</cell></row><row><cell>53 moderately poverty related (Type II)</cell></row><row><cell>28 strongly poverty related (Type III)</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 3</head><label>3</label><figDesc></figDesc><table><row><cell cols="2">Of these: 26 poverty-related and neglected diseases (PRND)</cell><cell>4 PRND defined by</cell></row><row><cell cols="2">as defined by G-FINDER,causing 343 million DALYs in 2010</cell><cell>G-FINDER but</cell></row><row><cell cols="2">(13.8 % of total) and receiving 3.6 billion US$ R&amp;D expenditure</cell><cell>not included in</cell></row><row><cell cols="2">(2008-2012 annual average, 1.34% of total) (G-FINDER 2014).</cell><cell>GBD 2010.</cell></row><row><cell>67 risk factors and</cell><cell>Table 4</cell></row><row><cell>risk factor clusters</cell><cell></cell></row><row><cell>(Income Relation</cell><cell cols="2">26 poverty-related and neglected diseases, Neglect</cell></row><row><cell>Factor ranging</cell><cell cols="2">Factor ranging from</cell></row><row><cell>from 0.4 to 421.3)</cell><cell>0.04 to 544</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 4</head><label>4</label><figDesc><div><p><s>26 poverty related and neglected diseases 15 Type III diseases -8Type II diseases -3Type Ia diseases</s></p></div></figDesc><table><row><cell>DALYs per 100,000 inhabitants in LMIC</cell><cell>Disease burden in DALYs (as % of the</cell></row><row><cell></cell><cell>total gobal disease burden)</cell></row><row><cell>DALYs per 100,000 inhabitants in HIC</cell><cell></cell></row></table><note><p><s>R D expenditure (as % of total global health -related R D expenditure) Fig. 1.</s><s>Data sources and analytical steps of our analysis of income relatedness and neglect in terms of research &amp; development (R&amp;D).</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_4"><head>Table 1 .</head><label>1</label><figDesc><div><p><s>The WHO classification of diseases according to their relatedness to the level of economic development and our proposed substratification and nomenclature</s></p></div></figDesc><table><row><cell>Verbal definition of the WHO</cell><cell>Operationalization proposed by</cell><cell></cell></row><row><cell>Commission on Macroeconomics</cell><cell>the WHO Secretariat (18) and</cell><cell>Our proposed substratification</cell></row><row><cell>and Health in 2001</cell><cell>Røttingen et al. (13)</cell><cell>and nomenclature.</cell></row><row><cell>Disease type I 'Type I diseases are incident in both rich</cell><cell>Diseases for which the disease burden in</cell><cell>Type Ia diseases, or strongly</cell></row><row><cell>and poor countries, with large numbers</cell><cell>low-and middle-income countries (LMIC)</cell><cell>affluence-related diseases, with</cell></row><row><cell>of vulnerable population in both' (21).</cell><cell>is not more than three times higher than in</cell><cell>an income relation factor,</cell></row><row><cell></cell><cell>high-income countries (HIC), measured in</cell><cell>IRF B0.33.</cell></row><row><cell></cell><cell>DALYs (disability-adjusted life years) per</cell><cell>Type Ib diseases, or moderately</cell></row><row><cell></cell><cell>100,000 inhabitants (13, 18).</cell><cell>affluence-related diseases, with</cell></row><row><cell></cell><cell></cell><cell>0.33 ]IRF B0.66.</cell></row><row><cell></cell><cell></cell><cell>Type Ic diseases, or diseases</cell></row><row><cell></cell><cell></cell><cell>unrelated to the level of economic</cell></row><row><cell></cell><cell></cell><cell>development, with 0.66]IRFB3.</cell></row><row><cell>Disease type II Type II diseases 'are incident in both rich</cell><cell></cell><cell></cell></row><row><cell>and poor countries, but with a</cell><cell></cell><cell></cell></row><row><cell>substantial proportion of the cases in</cell><cell></cell><cell></cell></row><row><cell>poor countries'</cell><cell></cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_5"><head>Table 2 .</head><label>2</label><figDesc><div><p><s>Relatedness of disease groups to the level of economic development</s></p></div></figDesc><table><row><cell>2010</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_9"><head>Table 3 .</head><label>3</label><figDesc><div><p><s>Relatedness of risk factors and risk factor clusters to the level of economic development</s></p></div></figDesc><table><row><cell>2010</cell></row></table><note><p><s>240 (175 Á 323) 197 (135 Á 276) 1.2 (0.6 Á 2.4) Ic (Ib-Ic) 107 (80 Á 139) 77 (61 Á 97) 1.4 (0.8 Á 2.3) Ic (Ic-Ic)</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_11"><head></head><label></label><figDesc><div><p><s>8)Ib(Ib-Ic)</s></p></div></figDesc><table><row><cell>Alcohol use</cell><cell cols="2">1,890 (1,630Á2,199) 2,208 (2,015Á2,422)</cell><cell>0.9 (0.7Á1.1)</cell><cell cols="3">Ic (Ic-Ic) 1,793 (1,555Á2,094) 2,919 (2,686Á3,179)</cell><cell>0.6 (0.5Á0.8)</cell><cell>Ib (Ib-Ic)</cell></row><row><cell>Drug use</cell><cell>316 (228Á431)</cell><cell>527 (404Á674)</cell><cell>0.6 (0.3Á1.1)</cell><cell>Ib (Ib-Ic)</cell><cell>250 (178Á353)</cell><cell>480 (370Á617)</cell><cell>0.5 (0.3Á1.0)</cell><cell>Ib (Ia-Ic)</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_13"><head>Table 3 (</head><label>3</label><figDesc><div><p><s>Continued )</s></p></div></figDesc><table><row><cell>2010</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_15"><head>Table 3 (</head><label>3</label><figDesc><div><p><s>Own calculations based on Global Burden of Disease Study 2010 data.</s><s>DALYs: disability-adjusted life years; LMIC: low-and middle-income countries; HIC: high-income countries; IRF: income relation factor, ratio of DALYs per 100,000 inhabitants in LMIC versus HIC; Risk factor Type Ia: strongly affluence-related risk factors; Ib: moderately affluence related; Ic: unrelated to the level of economic development; II: moderately poverty related; III: strongly poverty related.</s><s>Figures in parentheses represent 95% uncertainty intervals.</s><s>For details see statistical appendix.</s></p></div></figDesc><table><row><cell>2010</cell></row><row><cell>Continued )</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_16"><head>Global disease burden and R&amp;D expenditure compared</head><label></label><figDesc><div><p><s>Fig. 2. Disease burden in DALYs (as % of total global disease burden, 2010) and R&amp;D Expenditure (as % of total global health R&amp;D Expenditure, annual average for 2008Á2010) for 11 diseases and disease groups as defined by G-FINDER.</s><s>Source: Own calculation based on Global Burden of Disease Study 2010 and G-FINDER data and data published by Chakma et al.</s><s>DALYs: disability adjusted life years; R&amp;D: research and development.</s></p></div></figDesc><table><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="3">Poverty-related and neglected diseases</cell></row><row><cell>Leprosy</cell><cell cols="2">0.00% 0.00%</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Trachoma Dengue</cell><cell cols="2">0.03% 0.01% 0.00% 0.08%</cell><cell></cell><cell></cell><cell></cell><cell cols="6">Global disease burden, as % of the total global disease burden in DALYs, 2010</cell></row><row><cell>Kinetoplastids</cell><cell cols="3">0.18% 0.06% %</cell><cell></cell><cell></cell><cell cols="6">R&amp;D expenditure, as % of total worldwide health-related R&amp;D expenditure, 2008-2012 annual average</cell></row><row><cell>Rheumatic fever</cell><cell cols="2">0.00%</cell><cell>0.41%</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Helminths (Worms &amp; Flukes)</cell><cell cols="2">0.03%</cell><cell></cell><cell>0.49%</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Salmonella infections</cell><cell cols="2">0.02%</cell><cell></cell><cell></cell><cell>0.69%</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Bact. Pneumonia &amp; Meningitis</cell><cell cols="2">0.04%</cell><cell></cell><cell></cell><cell></cell><cell>1.61%</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Diarrhoeal diseases</cell><cell cols="2">0.07%</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>1.82%</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Tuberculosis</cell><cell></cell><cell cols="2">0.23% %</cell><cell></cell><cell></cell><cell></cell><cell>1.98%</cell><cell></cell><cell></cell><cell></cell></row><row><cell>HIV AIDS</cell><cell></cell><cell></cell><cell>0.48%</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>3.27%</cell><cell></cell></row><row><cell>Malaria</cell><cell></cell><cell cols="2">0.24 4%</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>3.32%</cell><cell></cell></row><row><cell cols="2">0.00%</cell><cell cols="2">0.50%</cell><cell>1.00%</cell><cell>1.50%</cell><cell>2.00%</cell><cell>2.50%</cell><cell>3.00%</cell><cell>3.50%</cell><cell>4.00%</cell><cell>4.50%</cell><cell>5.00%</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="2">% of total</cell><cell></cell><cell></cell><cell></cell></row></table><note><p><s>Citation: Glob Health Action 2015, 8: 25818http://dx.doi.org/10.3402/gha.v8.25818</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_17"><head>Table 4 .</head><label>4</label><figDesc><div><p><s>(25)expenditure (2008Á2012 annual average) and disease burden (2010) comparedOwn calculations based on Global Burden of Disease Study 2010 and G-FINDER data and data published by Chakma et al.(25).</s><s>DALYs: disability-adjusted life years; LMIC: low-and middle-income countries; HIC: high-income countries; IRF: income relation factor, ratio of DALYs per 100,000 inhabitants in LMIC versus HIC; Disease Type Ia: strongly affluence-related diseases; Ib: moderately affluence related; Ic: unrelated to the level of economic development; II: moderately poverty related; III: strongly poverty related.</s><s>aDisease not prevalent in HIC.</s></p></div></figDesc><table><row><cell>Cause or cause group All causes All G-FINDER diseases HIV AIDS</cell><cell>DALYs (% of total) 100 (100Á100) 13.82 (10.35Á18.14) 3.27 (2.81Á3.80)</cell><cell>R&amp;D (% of total) 100.00 1.34 0.48</cell><cell>Neglect factor 1 (1Á1) 10.3 (7.7Á13.6) 6.9 (5.9Á8.0)</cell><cell>Dollar per DALY 107 (83Á139) 10 (8Á13) 16 (14Á17)</cell><cell cols="3">DALYs per 100,000 inhabitants LMIC HIC 38041.42 (27279.01Á52476.16) 26421.32 (19916.73Á34930.07) 1.44 (.78Á2.63) IRF 5808.1 (4,243Á7,765) 468.9 (385Á573) 12.4 (7Á20) 1376.3 (1,188Á1,571) 108.9 (98Á121) 12.6 (10Á16)</cell><cell>Disease type Ic (Ic-Ic) II (II-II) II (II-II)</cell><cell>Peter von Philipsborn et al.</cell></row><row><cell>Malaria</cell><cell>3.32 (2.40Á4.68)</cell><cell>0.24</cell><cell>13.7 (9.9Á19.3)</cell><cell>8 (6Á10)</cell><cell>1414.6 (961Á2,050)</cell><cell>0.1 (0Á1)</cell><cell cols="2">11465.2 (1,268Á1,303,421) III (III-III)</cell></row><row><cell>Tuberculosis</cell><cell>1.98 (1.52Á2.39)</cell><cell>0.23</cell><cell>8.8 (6.7Á10.6)</cell><cell>12 (11Á15)</cell><cell>837.9 (654Á1,010)</cell><cell>41.4 (34Á51)</cell><cell>20.3 (13Á30)</cell><cell>II (II-II)</cell></row><row><cell>Diarrheal diseases</cell><cell>1.82 (1.35Á2.37)</cell><cell>0.07</cell><cell>27.1 (20.0Á35.2)</cell><cell>4 (3Á5)</cell><cell>769.0 (533Á1,068)</cell><cell>47.3 (31Á70)</cell><cell>16.3 (8Á35)</cell><cell>II (II-II)</cell></row><row><cell>Rotavirus</cell><cell>0.75 (.55Á.97)</cell><cell>0.02</cell><cell>34.6 (25.3Á44.8)</cell><cell>3 (3Á4)</cell><cell>315.8 (221Á428)</cell><cell>18.7 (12Á27)</cell><cell>16.9 (8Á35)</cell><cell>II (II-II)</cell></row><row><cell>Enterotoxigenic E. coli (ETEC)</cell><cell>0.28 (.21Á.35)</cell><cell>0.00</cell><cell>104.8 (80.7Á133.6)</cell><cell>1 (1Á1)</cell><cell>114.9 (83Á155)</cell><cell>17.5 (11Á26)</cell><cell>6.6 (3Á14)</cell><cell>II (II-II)</cell></row><row><cell>Cholera</cell><cell>0.18 (.13Á.25)</cell><cell>0.01</cell><cell>14.9 (10.5Á20.5)</cell><cell>7 (6Á10)</cell><cell>76.3 (46Á119)</cell><cell>0.0 (0Á0)</cell><cell>3156.8 (708Á13,273)</cell><cell>III (III-III)</cell></row><row><cell>Shigella</cell><cell>0.28 (.22Á.36)</cell><cell>0.01</cell><cell>30.9 (23.5Á39.4)</cell><cell>3 (3Á4)</cell><cell>119.3 (87Á162)</cell><cell>7.5 (5Á11)</cell><cell>15.9 (8Á33)</cell><cell>II (II-II)</cell></row><row><cell>Cryptosporidium</cell><cell>0.34 (.25Á.44)</cell><cell>0.00</cell><cell>82.5 (60.2Á108.7)</cell><cell>1 (1Á2)</cell><cell>142.6 (95Á205)</cell><cell>3.6 (2Á6)</cell><cell>39.8 (15Á107)</cell><cell>III (II-III)</cell></row><row><cell>Dengue</cell><cell>0.03 (.01Á.06)</cell><cell>0.08</cell><cell>0.4 (.2Á.7)</cell><cell>266 (155Á637)</cell><cell>13.3 (5Á29)</cell><cell>4.7 (2Á8)</cell><cell>2.9 (1Á14)</cell><cell>Ic (Ib-II)</cell></row><row><cell>Kinetoplastids</cell><cell>0.18 (.10Á.33)</cell><cell>0.06</cell><cell>2.8 (1.5Á5.3)</cell><cell>38 (22Á66)</cell><cell>74.7 (38Á140)</cell><cell>5.4 (3Á11)</cell><cell>13.9 (3Á55)</cell><cell>II (II-III)</cell></row><row><cell>Chagas disease</cell><cell>0.02 (.01Á.04)</cell><cell>0.01</cell><cell>2.3 (1.1Á4.7)</cell><cell>46 (24Á93)</cell><cell>8.5 (4Á18)</cell><cell>4.9 (2Á10)</cell><cell>1.7 (0Á8)</cell><cell>Ic (Ib-II)</cell></row><row><cell>Leishmaniasis</cell><cell>0.13 (.08Á.21)</cell><cell>0.02</cell><cell>5.5 (3.4Á8.6)</cell><cell>19 (13Á30)</cell><cell>56.7 (33Á92)</cell><cell>0.5 (0Á1)</cell><cell>117.7 (45Á290)</cell><cell>III (III-III)</cell></row><row><cell>Sleeping sickness</cell><cell>0.02 (.00Á.08)</cell><cell>0.02</cell><cell>1.4 (.2Á4.6)</cell><cell>78 (25Á574)</cell><cell>9.6 (1Á30)</cell><cell>Á</cell><cell>a</cell><cell>III (III-III)</cell></row><row><cell>Helminths (worms &amp; flukes)</cell><cell>0.49 (.27Á.88)</cell><cell>0.03</cell><cell>14.9 (8.0Á26.7)</cell><cell>7 (4Á13)</cell><cell>209.6 (114Á381)</cell><cell>1.6 (1Á3)</cell><cell>130.4 (37Á479)</cell><cell>III (III-III)</cell></row><row><cell>Roundworm (ascariasis)</cell><cell>0.05 (.03Á.10)</cell><cell>0.00</cell><cell>63.3 (32.4Á119.9)</cell><cell>2 (1Á3)</cell><cell>22.4 (12Á40)</cell><cell>0.4 (0Á1)</cell><cell>50.6 (12Á205)</cell><cell>III (II-III)</cell></row><row><cell>Hookworm (Ancylostomiasis &amp;</cell><cell>0.13 (.06Á.24)</cell><cell>0.00</cell><cell>34.3 (17.0Á64.5)</cell><cell>3 (2Á6)</cell><cell>55.1 (27Á102)</cell><cell>0.9 (0Á2)</cell><cell>59.5 (16Á212)</cell><cell>III (II-III)</cell></row><row><cell>Nectoriasis)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Whipworm (trichuriasis)</cell><cell>0.03 (.01Á.05)</cell><cell>0.00</cell><cell>60.3 (31.2Á106.3)</cell><cell>2 (1Á3)</cell><cell>10.9 (6Á18)</cell><cell>0.0 (0Á0)</cell><cell>1110.4 (323Á3,864)</cell><cell>III (III-III)</cell></row><row><cell>Lymphatic filariasis (elephantiasis)</cell><cell>0.11 (.07Á.17)</cell><cell>0.01</cell><cell>19.4 (11.9Á29.7)</cell><cell>5 (4Á8)</cell><cell>47.5 (31Á69)</cell><cell>Á</cell><cell>a</cell><cell>III (III-III)</cell></row><row><cell>Onchocerciasis (river blindness)</cell><cell>0.02 (.01Á.03)</cell><cell>0.00</cell><cell>4.8 (3.3Á6.8)</cell><cell>22 (17Á30)</cell><cell>8.5 (6Á11)</cell><cell>Á</cell><cell>a</cell><cell>III (III-III)</cell></row><row><cell>Schistosomiasis (bilharziasis)</cell><cell>0.13 (.06Á.27)</cell><cell>0.01</cell><cell>13.0 (6.3Á26.1)</cell><cell>8 (4Á16)</cell><cell>56.6 (27Á127)</cell><cell>Á</cell><cell>a</cell><cell>III (III-III)</cell></row><row><cell>Tapeworm (cysticercosis/taeniasis)</cell><cell>0.02 (.01Á.03)</cell><cell>0.00</cell><cell>19.1 (13.5Á26.6)</cell><cell>6 (4Á7)</cell><cell>8.6 (6Á13)</cell><cell>0.2 (0Á0)</cell><cell>37.7 (13Á116)</cell><cell>III (II-III)</cell></row><row><cell>Bacterial pneumonia &amp; meningitis</cell><cell>1.61 (1.33Á1.91)</cell><cell>0.04</cell><cell>41.3 (34.1Á48.9)</cell><cell>3 (2Á3)</cell><cell>654.9 (528Á805)</cell><cell>178.6 (151Á209)</cell><cell>3.7 (3Á5)</cell><cell>II (Ic-II)</cell></row><row><cell>Streptococcus pneumoniae</cell><cell>1.40 (1.16Á1.66)</cell><cell>0.03</cell><cell>51.1 (42.4Á60.4)</cell><cell>2 (2Á2)</cell><cell>567.9 (458Á697)</cell><cell>171.0 (145Á200)</cell><cell>3.3 (2Á5)</cell><cell>II (Ic-II)</cell></row><row><cell>Neisseria meningitidis</cell><cell>0.21 (.17Á.25)</cell><cell>0.01</cell><cell>35.2 (28.3Á42.6)</cell><cell>3 (3Á4)</cell><cell>87.0 (70Á107)</cell><cell>7.6 (6Á9)</cell><cell>11.4 (8Á17)</cell><cell>II (II-II)</cell></row><row><cell>Salmonella infections</cell><cell>0.69 (.21Á1.23)</cell><cell>0.02</cell><cell>35.9 (10.9Á64.5)</cell><cell>3 (2Á9)</cell><cell>289.7 (83Á513)</cell><cell>14.7 (8Á23)</cell><cell>19.6 (4Á65)</cell><cell>II (II-III)</cell></row><row><cell>Non-typhoidal Salmonella enterica</cell><cell>0.19 (.14Á.25)</cell><cell>0.01</cell><cell>29.7 (22.1Á38.6)</cell><cell>4 (3Á5)</cell><cell>81.1 (55Á117)</cell><cell>10.5 (7Á15)</cell><cell>7.7 (4Á16)</cell><cell>II (II-II)</cell></row><row><cell>(NTS)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Typhoid and paratyphoid fever</cell><cell>0.49 (.06Á.98)</cell><cell>0.01</cell><cell>56.4 (7.4Á112.6)</cell><cell>2 (1Á14)</cell><cell>208.7 (28Á395)</cell><cell>4.2 (1Á8)</cell><cell>49.4 (3Á725)</cell><cell>III (II-III)</cell></row><row><cell>(S. typhi, S. paratyphi A)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Leprosy</cell><cell>0.00 (.00Á.00)</cell><cell>0.00</cell><cell>0.1 (.0Á.1)</cell><cell>1,914 (1,026Á4,361)</cell><cell>0.1 (0Á0)</cell><cell>0.0 (0Á0)</cell><cell>65.8 (8Á1,110)</cell><cell>III (II-III)</cell></row><row><cell>Rheumatic fever</cell><cell>0.41 (.34Á.48)</cell><cell>0.00</cell><cell>544.2 (458.6Á642.8)</cell><cell>0 (0Á0)</cell><cell>162.1 (136Á190)</cell><cell>66.2 (58Á76)</cell><cell>2.4 (2Á3)</cell><cell>Ic (Ic-II)</cell></row><row><cell>Trachoma</cell><cell>0.01 (.01Á.02)</cell><cell>0.00</cell><cell>5.8 (4.0Á8.0)</cell><cell>18 (14Á25)</cell><cell>5.7 (4Á8)</cell><cell>Á</cell><cell>a</cell><cell>III (III-III)</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_18"><head>US Dollar R&amp;D Expenditure per disability-adjusted life year, 2008-2012 annual average)</head><label></label><figDesc></figDesc><table><row><cell cols="7">$78.21 Dollar/DALY ((95CI: 25-574) $46.00 $37.52 $22.17 $19.39 $18.47 $15.52 $12.18 $10.33 $8.21 $7.79 $7.17 $7.16 $5.60 $5.50 $3.94 $3.60 $3.45 $3.11 $3.08 $3.03 $2.98 $2.59 $2.09 $1.89 $1.77 $1.69 $1.29 $1.02 $0.20 Sleeping Sickness Chagas' disease Kinetoplastids Onchocerciasis (river blindness) Leishmaniasis Trachoma HIV AIDS Tuberculosis Schistosomiasis (bilharziasis) Malaria Cholera Helminths (Worms &amp; Flukes) Tapeworm (cysticercosis/taeniasis) Lymphatic filariasis (elephantiasis) Diarrhoeal diseases Non-typhoidal Salmonella enterica Shigella Hookworm (Ancylostm./Nectoriasis) Rotavirus Neisseria meningitidis Salmonella infections Bacterial Pneumonia &amp; Meningitis Streptococcus pneumoniae Typhoid and paratyphoid fever Whipworm (trichuriasis) Roundworm (ascariasis) Cryptosporidium Enterotoxigenic E. coli (ETEC) Rheumatic Fever All PRND (G-</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>$106.70</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Dengue</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="2">$266 (95CI: 155-637)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Leprosy</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="4">$1914 (95CI: 1026-4361)</cell></row><row><cell>$0</cell><cell>$20</cell><cell>$40</cell><cell>$60</cell><cell>$80</cell><cell>$100</cell><cell>$120</cell><cell>$140</cell><cell>$160</cell><cell>$180</cell><cell>$200</cell></row><row><cell></cell><cell></cell><cell cols="7">US$ R&amp;D expenditure (2008-2012 annual average) per DALY (2010)</cell><cell></cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_19"><head>FINDER definition) All causes of death and disability</head><label></label><figDesc><div><p><s>Fig. 3. R&amp;D expenditure (2008Á2012 annual average, in 2012 nominal US$) per DALY (2010).</s><s>Source: Own calculations based on Global Burden of Disease Study 2010, G-FINDER data and data published by Chakma et al.</s><s>DALYs: disability adjusted life years; R&amp;D: research and development.</s></p></div></figDesc><table><row><cell>Poverty-related and neglected diseases</cell></row></table><note><p><s>Citation: Glob Health Action 2015, 8: 25818http://dx.doi.org/10.3402/gha.v8.25818</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_20"><head></head><label></label><figDesc><div><p><s>et al. showed that in 2010 roughly 1% of global health-related R&amp;D investment was spent on PRND (13).</s><s>Pedrique et al. show that only 1% of clinical trials registered between 1999 and 2011 are devoted to PRND and between 2000 and 2011 only 1.2% of new chemical entities were developed for PRND that accounted for 11% of global disease burden (3, 7).</s><s>Hotez et al. and Viergever found large variations between selected PRND when estimating neglect in R&amp;D using the Dollar/DALY metric (6, 22).</s><s>Evans et al. analyze the number of articles, systematic reviews, and clinical trials indexed in MEDLINE for 111 prominent medical conditions, and found that</s></p></div></figDesc><table><row><cell cols="5">The Neglect Factor -Disease Burden versus R&amp;D Expenditure</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Rheumatic Fever</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="3">544.2 (95CI: 459-643)</cell></row><row><cell>Enterotoxigenic E. coli (ETEC)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>104.8</cell><cell></cell><cell></cell></row><row><cell>Cryptosporidium</cell><cell></cell><cell></cell><cell></cell><cell>82.5</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Roundworm (ascariasis)</cell><cell></cell><cell></cell><cell>63.3</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Whipworm (trichuriasis)</cell><cell></cell><cell></cell><cell>60.3</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Typhoid and paratyphoid fever</cell><cell></cell><cell></cell><cell>56.4</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Streptococcus pneumoniae</cell><cell></cell><cell></cell><cell>51.1</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Bacterial Pneumonia &amp; Meningitis</cell><cell></cell><cell>41.3</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Salmonella infections</cell><cell></cell><cell>35.9</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Neisseria meningitidis</cell><cell></cell><cell>35.2</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Rotavirus</cell><cell></cell><cell>34.6</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Hookworm (Ancylosto./Nectoriasis)</cell><cell></cell><cell>34.3</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Shigella</cell><cell></cell><cell>30.9</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Non-typhoidal Salmonella enterica</cell><cell></cell><cell>29.7</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Diarrhoeal diseases</cell><cell cols="2">27.1</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Lymphatic filariasis (elephantiasis)</cell><cell>19.4</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Tapeworm (cysticercosis/taeniasis)</cell><cell>19.1</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Helminths (Worms &amp; Flukes)</cell><cell>14.9</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Cholera</cell><cell>14.9</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Malaria</cell><cell>13.7</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Schistosomiasis (bilharziasis)</cell><cell>13.0</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>All PRND (G-FINDER definition)</cell><cell>10.3</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Tuberculosis</cell><cell>8.8</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>HIV AIDS</cell><cell>6.9</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Trachoma</cell><cell>5.8</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Leishmaniasis</cell><cell>5.5</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Onchocerciasis (river blindness)</cell><cell>4.8</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Kinetoplastids</cell><cell>2.8</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Chagas' disease</cell><cell>2.3</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Sleeping Sickness</cell><cell>1.4</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>All causesof death and disability</cell><cell>1.0</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Dengue</cell><cell>0.4</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Leprosy</cell><cell>0.1</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>00</cell><cell>20</cell><cell>40</cell><cell>60</cell><cell>80</cell><cell>100</cell><cell>120</cell><cell>140</cell></row><row><cell></cell><cell cols="6">Neglect Factor (disease burden as % of total / R&amp;D expenditure as % of total)</cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_21"><head></head><label></label><figDesc><div><p><s>disease burden caused by individual diseases, disease groups, and risk factors varies strongly with the level of economic development, as demonstrated by the wide range of the IRF.</s><s>Communicable, neonatal, maternal, and nutritional disorders cause a 10 times larger disease burden per capita in LMIC than in HIC (IRF 10.3).</s><s>Non-communicable diseases cause only a slightly smaller disease burden per capita in LMIC than in HIC (IRF 0.8), demonstrating the double burden of communicable and non-communicable diseases in LMIC.</s><s>The 26 povertyrelated diseases included in our analysis of neglect in</s></p></div></figDesc><table><row><cell>18%</cell><cell></cell><cell></cell><cell></cell></row><row><cell>16%</cell><cell></cell><cell>15.66% (sum)</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell>13.82%</cell></row><row><cell>14%</cell><cell></cell><cell></cell><cell>(sum)</cell></row><row><cell></cell><cell></cell><cell>4.01%</cell><cell></cell></row><row><cell cols="2">2.76%</cell><cell></cell><cell></cell></row><row><cell>12%</cell><cell></cell><cell></cell><cell>3.32%</cell></row><row><cell cols="2">0.72%</cell><cell></cell><cell></cell></row><row><cell cols="2">2.45% 10%</cell><cell>3.81%</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell>3.27%</cell></row><row><cell>8%</cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="2">3.88% 6%</cell><cell>2.24%</cell><cell>1.98%</cell></row><row><cell>4%</cell><cell></cell><cell>2.06%</cell><cell>1.82%</cell></row><row><cell cols="2">2.34%</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>1.70%</cell><cell>1.61%</cell></row><row><cell>2%</cell><cell>0.75%</cell><cell></cell><cell></cell></row><row><cell></cell><cell>0.58%</cell><cell>0.67%</cell><cell>0.69%</cell></row><row><cell>0%</cell><cell>0.34% 0.58%</cell><cell>0.50% 0.44% 0.20%</cell><cell>0.49% 0.41% 0.18%</cell></row></table></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">(page number not for citation purpose)</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">(page number not for citation purpose)Citation: Glob Health Action 2015, 8: 25818http://dx.doi.org/10.3402/gha.v8.25818</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgements</head><p><s>We thank the editor and two anonymous reviewers for their constructive comments, which helped us to improve the manuscript.</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>R&amp;D are responsible for 13.8% of the global disease burden, but receive only 1.34% of global health-related R&amp;D expenditure.</s><s>These findings reveal a considerable shortfall in R&amp;D funding for PRND.</s><s>The degree of neglect, however, as captured by the Dollar per DALY metric and the NF, varies considerably among the different PRND.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Authors' contributions</head><p><s>PvP and FS wrote the article and did the statistical analysis with input from MB, SR, and PT.</s><s>MB, SR, and PT provided conceptual input and research support.</s><s>PT provided guidance on the implementation of the work.</s><s>All authors have seen and approved the final version of the abstract for publication.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Competing interests and funding</head><p><s>This work was supported by the German Research Foundation (DFG) and the Technische Universita ¨t Mu ¨nchen within the funding programme Open Access Publishing.</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Global health 2035: a world converging within a generation</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">T</forename><surname>Jamison</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">H</forename><surname>Summers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Alleyne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">J</forename><surname>Arrow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Berkley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Binagwaho</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">382</biblScope>
			<biblScope unit="page" from="1898" to="1955" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Convergence of non-communicable and infectious diseases in low-and middle-income countries</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">V</forename><surname>Remais</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Zeng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Tian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Engelgau</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Epidemiol</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="page" from="221" to="227" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Attention to local health burden and the global disparity of health research</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Evans</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J-M</forename><surname>Shim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jpa</forename><surname>Ioannidis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS One</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page">e90147</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Medical innovation for neglected patients: important progress over past ten years, but &apos;&apos;fatal Imbalance&apos;&apos; persists. Me ´decins Sans Frontie `res. Drugs for Neglected Diseases Initiative</title>
		<ptr target="https://www.aerzte-ohne-grenzen.de/sites/germany/files/attachments/2012-12-13-medical-innovations-for-neglected-patients.pdf" />
	</analytic>
	<monogr>
		<title level="m">Drugs for Neglected Diseases Initiative</title>
				<imprint>
			<date type="published" when="2012">2012. 2014</date>
		</imprint>
	</monogr>
	<note>cited 30 October</note>
</biblStruct>

<biblStruct xml:id="b4">
	<monogr>
		<title level="m" type="main">Research and development to meet health needs in developing countries: strengthening global financing and coordination. Report of the Consultative Expert Working Group on Research and Development: financing and coordination</title>
		<ptr target="http://www.who.int/phi/CEWG_Report_5_April_2012.pdf" />
		<imprint>
			<date type="published" when="2012">2012. 2014</date>
		</imprint>
	</monogr>
	<note>cited 30 October</note>
</biblStruct>

<biblStruct xml:id="b5">
	<monogr>
		<title level="m" type="main">The mismatch between the health research and development (R&amp;D) that is needed and the R&amp;D that 520 is undertaken: an overview of the problem, the causes, and solutions. Glob Health Action</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">F</forename><surname>Viergever</surname></persName>
		</author>
		<idno type="DOI">10.3402/gha.v6i0.22450</idno>
		<ptr target="http://dx.doi.org/10.3402/gha.v6i0.22450" />
		<imprint>
			<date type="published" when="2013">2013</date>
			<biblScope unit="page">L22450</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">The drug and vaccine landscape for neglected diseases (2000Á11): a systematic assessment</title>
		<author>
			<persName><forename type="first">B</forename><surname>Pedrique</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Strub-Wourgaft</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Some</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Olliaro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Trouiller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Ford</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Glob Health</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="page" from="371" to="e379" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">A breakthrough in R&amp;D for neglected diseases: new ways to get the drugs we need</title>
		<author>
			<persName><forename type="first">M</forename><surname>Moran</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS Med</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page">e302</biblScope>
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Rescuing the bottom billion through control of neglected tropical diseases</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Hotez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Fenwick</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Savioli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">H</forename><surname>Molyneux</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">373</biblScope>
			<biblScope unit="page" from="1570" to="1575" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Neglected disease research and development: how much are we really spending</title>
		<author>
			<persName><forename type="first">M</forename><surname>Moran</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Guzman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A-L</forename><surname>Ropars</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Mcdonald</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Jameson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Omune</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS Med</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page">e1000030</biblScope>
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Drug development for neglected diseases: a deficient market and a public-health policy failure</title>
		<author>
			<persName><forename type="first">P</forename><surname>Trouiller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Olliaro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Torreele</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Orbinski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Laing</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Ford</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">359</biblScope>
			<biblScope unit="page" from="2188" to="2194" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">The global drug gap</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Reich</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Science</title>
		<imprint>
			<biblScope unit="volume">287</biblScope>
			<date type="published" when="2000">2000. 1979Á81</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Mapping of available health research and development data: what&apos;s there, what&apos;s missing, and what role is there for a global observatory</title>
		<author>
			<persName><forename type="first">J-A</forename><surname>Røttingen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Regmi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Eide</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Young</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">F</forename><surname>Viergever</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">382</biblScope>
			<biblScope unit="page" from="1286" to="1307" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<monogr>
		<title level="m" type="main">Draft working paper: a global health R&amp;D observatory Á developing a case for its development</title>
		<ptr target="http://www.who.int/phi/documents/dwp1_global_health_rd_observatory_16May13.pdf" />
		<imprint>
			<date type="published" when="2013">2013. 2014</date>
		</imprint>
	</monogr>
	<note>cited 30 October</note>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">A new deal for global health R&amp;D? The recommendations of the Consultative Expert Working Group on Research and Development (CEWG)</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Rottingen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Chamas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS Med</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page">e1001219</biblScope>
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Innovation and access to medicines for neglected populations: could a treaty address a broken pharmaceutical R&amp;D system</title>
		<author>
			<persName><forename type="first">S</forename><surname>Moon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Bermudez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">'</forename><surname>Hoen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS Med</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page">e1001218</biblScope>
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<monogr>
		<title level="m" type="main">Resolution WHA66.22: follow up of the report of the Consultative Expert Working Group on Research and Development: financing and coordination</title>
		<imprint>
			<date type="published" when="2013">2013</date>
			<publisher>WHO</publisher>
			<pubPlace>Geneva</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<monogr>
		<title level="m" type="main">Defining disease types I, II and III Á background document provided by the WHO secretariat</title>
		<imprint>
			<date type="published" when="2012">2012</date>
			<publisher>WHO</publisher>
			<pubPlace>Geneva</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990Á2010: a systematic analysis for the Global Burden of Disease Study</title>
		<author>
			<persName><forename type="first">Cjl</forename><surname>Murray</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Vos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Lozano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Naghavi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Flaxman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Michaud</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">380</biblScope>
			<biblScope unit="page" from="2197" to="2223" />
			<date type="published" when="2010">2010. 2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 19 90Á2010: a systematic analysis for the Global Burden of Disease Study</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">S</forename><surname>Lim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Vos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Flaxman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Danaei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Shibuya</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Adair-Rohani</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">380</biblScope>
			<biblScope unit="page" from="2224" to="2260" />
			<date type="published" when="2010">2010. 2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Macroeconomics and health: investing in health for economic development</title>
		<ptr target="http://whqlibdoc.who.int/publications/2001/924154550x.pdf" />
	</analytic>
	<monogr>
		<title level="j">WHO</title>
		<imprint>
			<date type="published" when="2001">2001. 2014</date>
		</imprint>
	</monogr>
	<note>Report of the Commission on Macroeconomics and Health. cited 30 October</note>
</biblStruct>

<biblStruct xml:id="b21">
	<monogr>
		<title level="m" type="main">Strengthening mechanisms to prioritize, coordinate, finance, and execute R&amp;D to meet health needs in developing countries</title>
		<author>
			<persName><forename type="first">S</forename><surname>Hotez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Cohen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Mimura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Yamada</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Hoffman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Patel</surname></persName>
		</author>
		<ptr target="http://iom.edu/Â/media/Files/Perspectives-Files/2013/Discussion-Papers/BGH-GlobalHealthRD.pdf" />
		<imprint>
			<date type="published" when="2014-01">January 2014</date>
			<biblScope unit="page">10</biblScope>
		</imprint>
	</monogr>
	<note>Institute of Medicine, Discussion paper. 2013. Available from</note>
</biblStruct>

<biblStruct xml:id="b22">
	<monogr>
		<title level="m" type="main">Neglected disease research and development: the public divide. G-FINDER Policy Cures</title>
		<author>
			<persName><forename type="first">M</forename><surname>Moran</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Guzman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Chapman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Abela-Oversteegen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Howard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Farrell</surname></persName>
		</author>
		<ptr target="http://www.policycures.org/downloads/GF_report13_all_web.pdf" />
		<imprint>
			<date type="published" when="2013">2013. 2014</date>
		</imprint>
	</monogr>
	<note>cited 30 October</note>
</biblStruct>

<biblStruct xml:id="b23">
	<monogr>
		<title level="m" type="main">public search tool: policy cures</title>
		<author>
			<persName><forename type="first">G-Finder</forename></persName>
		</author>
		<ptr target="http://g-finder.policycures.org/gfinder_report/search" />
		<imprint>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note>cited 1 August 2014</note>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Asia&apos;s ascent Á global trends in biomedical R&amp;D expenditures</title>
		<author>
			<persName><forename type="first">J</forename><surname>Chakma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">H</forename><surname>Sun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Steinberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Sammut</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Jagsi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">370</biblScope>
			<biblScope unit="page" from="3" to="6" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<monogr>
		<title level="m" type="main">Health research Á essential link to equity in development. Commission on Health Research for Development</title>
		<ptr target="http://www.cohred.org/publications/open-archive/1990-commission-report/" />
		<imprint>
			<date type="published" when="1990">1990. 2014</date>
		</imprint>
		<respStmt>
			<orgName>Commission on Health Research for Development</orgName>
		</respStmt>
	</monogr>
	<note>cited 30 October</note>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Global biomedical R&amp;D expenditures</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Young</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">F</forename><surname>Terry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J-A</forename><surname>Røttingen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">F</forename><surname>Viergever</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">370</biblScope>
			<biblScope unit="page" from="2451" to="2452" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Parasites and poverty: the case of schistosomiasis</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">H</forename><surname>King</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Acta Tropica</title>
		<imprint>
			<biblScope unit="volume">113</biblScope>
			<biblScope unit="page" from="95" to="104" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Schistosomiasis, soil-transmitted helminthiasis, and sociodemographic factors influence quality of life of adults in Co ˆte d&apos;Ivoire</title>
		<author>
			<persName><forename type="first">T</forename><surname>Fu ¨rst</surname></persName>
		</author>
		<author>
			<persName><forename type="first">´kd</forename><surname>Silue</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ouattara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>'goran</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">N</forename><surname>Adiossan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">G</forename></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>'guessan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS Negl Trop Dis</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page">e1855</biblScope>
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Neglected tropical diseases: diagnosis, clinical management, treatment and control</title>
		<author>
			<persName><forename type="first">J</forename><surname>Utzinger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Becker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Knopp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Blum</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Neumayr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Keiser</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Swiss Med Wkly</title>
		<imprint>
			<biblScope unit="volume">142</biblScope>
			<biblScope unit="page">13727</biblScope>
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">NTDs V.2.0: &apos;&apos;blue marble health&apos;&apos; Á neglected tropical disease control and elimination in a shifting health policy landscape</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Hotez</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS Negl Trop Dis</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page">e2570</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Working to overcome the global impact of neglected tropical diseases. First WHO report on neglected tropical diseases</title>
		<ptr target="http://whqlibdoc.who.int/publications/2010/9789241564090_eng.pdf" />
	</analytic>
	<monogr>
		<title level="j">WHO</title>
		<imprint>
			<date type="published" when="2010">2010. 2014</date>
		</imprint>
	</monogr>
	<note>cited 30 October</note>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Development of and access to products for neglected diseases</title>
		<author>
			<persName><forename type="first">J</forename><surname>Cohen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Dibner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Wilson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS One</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page">e10610</biblScope>
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Use of data from registered clinical trials to identify gaps in health research and development</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">F</forename><surname>Viergever</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">F</forename><surname>Terry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Karam</surname></persName>
		</author>
		<idno type="DOI">10.3402/gha.v8.25818</idno>
		<ptr target="http://dx.doi.org/10.3402/gha.v8.25818" />
	</analytic>
	<monogr>
		<title level="j">Bull World Health Organ</title>
		<imprint>
			<biblScope unit="volume">91</biblScope>
			<biblScope unit="page">25818</biblScope>
			<date type="published" when="2013">2013. 2015</date>
		</imprint>
	</monogr>
	<note>Poverty-related and neglected diseases Citation: Glob Health Action</note>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
